A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2019
At a glance
- Drugs NIR 178 (Primary) ; Spartalizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colon cancer; Colorectal cancer; Diffuse large B cell lymphoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Dec 2018 Planned number of patients changed from 300 to 285.
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Planned End Date changed from 30 Jan 2021 to 6 Nov 2020.